PSNL
Personalis, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$17.20
+2.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 69.7M | 69.6M | 84.6M | 73.5M | 65.0M |
| Cost of Revenue | 60.8M | 53.9M | 57.8M | 55.3M | 51.7M |
| Gross Profit | 8.8M | 15.8M | 26.8M | 18.2M | 13.3M |
| Operating Expenses | |||||
| R&D Expense | 56.1M | 50.3M | 48.9M | 64.8M | 64.9M |
| SG&A Expense | 67.0M | 53.6M | 46.2M | 49.7M | 64.0M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 123.1M | 103.8M | 95.1M | 114.5M | 128.9M |
| Cost and Expenses | 184.0M | 157.7M | 152.9M | 169.8M | 180.6M |
| Operating Income (EBIT) | (114.3M) | (88.1M) | (68.3M) | (96.3M) | (115.5M) |
| Non-Operating | |||||
| Interest Income | 7.4M | 7.2M | 5.5M | 5.9M | 2.4M |
| Interest Expense | 213.0K | 205.0K | 24.0K | 110.0K | 201.0K |
| Net Interest Income | 7.2M | 7.0M | 5.5M | 5.8M | 2.2M |
| Other Non-Op Income/Expense | 7.2M | 6.8M | (13.0M) | (11.9M) | 2.3M |
| Non-Operating Income (excl Interest) | (7.4M) | (7.0M) | 13.0M | 11.8M | (2.5M) |
| EBT (Pre-Tax Income) | (107.1M) | (81.2M) | (81.3M) | (108.2M) | (113.3M) |
| Income Tax Expense | 33.0K | 21.0K | 18.0K | 83.0K | 40.0K |
| Bottom Line | |||||
| Net Income | (107.2M) | (81.3M) | (81.3M) | (108.3M) | (113.3M) |
| Earnings from Cont. Ops | (107.2M) | (81.3M) | (81.3M) | (108.3M) | (113.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (107.2M) | (81.3M) | (81.3M) | (108.3M) | (113.3M) |
| Per Share | |||||
| Basic EPS | ($1.09) | ($0.91) | ($1.37) | ($2.25) | ($2.48) |
| Diluted EPS | ($1.09) | ($0.91) | ($1.37) | ($2.25) | ($2.48) |
| Revenue Per Share | $0.66 | $0.78 | $1.43 | $1.53 | $1.42 |
| Shares | |||||
| Basic Shares Outstanding | 105.4M | 89.2M | 59.3M | 48.2M | 45.7M |
| Diluted Shares Outstanding | 105.4M | 89.2M | 59.3M | 48.2M | 45.7M |
| Profitability Metrics | |||||
| EBITDA | (97.2M) | (71.0M) | (70.3M) | (96.8M) | (104.6M) |
| D&A | 9.7M | 10.0M | 10.9M | 11.3M | 8.4M |
| EBIT | (106.9M) | (81.0M) | (81.2M) | (108.1M) | (113.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026